Vaxcyte, Inc.
PCVX
Κατάταξη σε μετοχές
#2067
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage,... Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
Τιμή μετοχής
$63.49
Κεφαλαιοποίηση
$9.99B
Αλλαγή (1 ημέρα)
-4.14%
Αλλαγή (1 έτος)
49.92%
Χώρα
US
Εμπόριο Vaxcyte, Inc. (PCVX)
Κατηγορία
Healthcare
Ιστορικό τιμής μετοχής για την Vaxcyte, Inc. (PCVX)
Υψηλότερη τιμή κλεισίματος: $65.58 στις 2026-10-01
Χαμηλότερη τιμή κλεισίματος: $32.16 στις 2020-06-01
Χαμηλότερη τιμή κλεισίματος: $32.16 στις 2020-06-01
Ιστορικό τιμής μετοχής της Vaxcyte, Inc. από 2020 έως 2026
Ετήσια απόδοση τιμής μετοχής
| Έτος | Απόδοση |
|---|---|
| 2026 (TTM) | 18.84% |
| 2025 | -48.18% |
| 2024 | 49.19% |
| 2023 | 30.50% |
| 2022 | 103.95% |
| 2021 | -26.14% |
| 2020 | 0.00% |
Τιμή μετοχής για παρόμοιες εταιρείες ή ανταγωνιστές
| Εταιρεία | Τιμή μετοχής | Μεταβολή 1Έτ% | Χώρα |
|---|---|---|---|
| $527.18 | 23.67% |
US
|
|
| $251.29 | 814.11% |
US
|
|
| $138.33 | -3.31% |
AU
|
|
| $890.85 | 6.72% |
NL
|
|
| $752.87 | 7.40% |
CH
|
